RS59048B1 - Terapeutski agensi za neurodegenerativne bolesti - Google Patents

Terapeutski agensi za neurodegenerativne bolesti

Info

Publication number
RS59048B1
RS59048B1 RS20190801A RSP20190801A RS59048B1 RS 59048 B1 RS59048 B1 RS 59048B1 RS 20190801 A RS20190801 A RS 20190801A RS P20190801 A RSP20190801 A RS P20190801A RS 59048 B1 RS59048 B1 RS 59048B1
Authority
RS
Serbia
Prior art keywords
leucine
acetyl
patient
disease
neurodegenerative disease
Prior art date
Application number
RS20190801A
Other languages
English (en)
Serbian (sr)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS59048(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of RS59048B1 publication Critical patent/RS59048B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20190801A 2016-08-11 2017-08-11 Terapeutski agensi za neurodegenerativne bolesti RS59048B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
EP17767934.7A EP3416631B1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
RS59048B1 true RS59048B1 (sr) 2019-08-30

Family

ID=59859424

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190801A RS59048B1 (sr) 2016-08-11 2017-08-11 Terapeutski agensi za neurodegenerativne bolesti

Country Status (28)

Country Link
US (3) US12144792B2 (enExample)
EP (3) EP3416631B1 (enExample)
JP (3) JP6957602B2 (enExample)
KR (4) KR20220093385A (enExample)
CN (4) CN116492328A (enExample)
AU (3) AU2017308865B2 (enExample)
BR (1) BR112019002730A2 (enExample)
CA (1) CA3033564A1 (enExample)
CY (1) CY1121930T1 (enExample)
DK (1) DK3416631T3 (enExample)
ES (1) ES2733677T3 (enExample)
HR (1) HRP20191055T1 (enExample)
HU (1) HUE045043T2 (enExample)
IL (3) IL264641B2 (enExample)
LT (1) LT3416631T (enExample)
MA (2) MA47521A (enExample)
MD (1) MD3416631T2 (enExample)
ME (1) ME03454B (enExample)
MX (3) MX383499B (enExample)
PL (1) PL3416631T3 (enExample)
PT (1) PT3416631T (enExample)
RS (1) RS59048B1 (enExample)
RU (1) RU2756519C2 (enExample)
SG (1) SG11201901063SA (enExample)
SI (1) SI3416631T1 (enExample)
SM (1) SMT201900370T1 (enExample)
TN (1) TN2019000033A1 (enExample)
WO (1) WO2018029658A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
ES2948135T3 (es) 2015-06-24 2023-08-31 Univ Michigan Regents Sistemas de terapia de histotripsia para el tratamiento del tejido cerebral
EP3416631B1 (en) 2016-08-11 2019-05-15 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
DK3482754T3 (da) * 2016-08-11 2021-02-01 Intrabio Ltd Farmaceutiske sammensætninger og anvendelser rettet mod lysosomale lagringssygdomme
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
MX2020003427A (es) * 2017-10-18 2020-09-14 Intrabio Ltd Agentes terapeuticos para enfermedades neurodegenerativas.
IL276576B2 (en) * 2018-02-15 2024-10-01 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
EP3886737A4 (en) 2018-11-28 2022-08-24 Histosonics, Inc. HISTOTRIPSY SYSTEMS AND METHODS
CN113348018B (zh) * 2018-12-06 2025-04-01 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
JP7555346B2 (ja) * 2019-03-02 2024-09-24 イントラビオ エルティーディー 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体
US20220346699A1 (en) * 2019-09-17 2022-11-03 Hoffmann-La Roche Inc. Improvements in Personalized Healthcare for Patients with Movement Disorders
CA3164545A1 (en) * 2020-01-13 2021-07-22 Michael Strupp Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
AU2023366591A1 (en) 2022-10-28 2025-04-24 Histosonics, Inc. Histotripsy systems and methods
WO2024221001A2 (en) 2023-04-20 2024-10-24 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
EP2124934B1 (en) 2007-02-22 2015-04-08 Beiersdorf AG Cosmetic and pharmaceutical applications of n-acetylhydroxyproline
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
MX378668B (es) * 2013-10-28 2025-03-10 Naurex Inc Profarmacos y moduladores de receptores nmda, sales y usos de estos.
KR102632670B1 (ko) 2016-04-19 2024-02-01 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
EP3416631B1 (en) 2016-08-11 2019-05-15 Intrabio Ltd Therapeutic agents for neurodegenerative diseases

Also Published As

Publication number Publication date
KR20190039227A (ko) 2019-04-10
SMT201900370T1 (it) 2019-09-09
IL264641B1 (en) 2024-03-01
IL310801A (en) 2024-04-01
EP3416631B1 (en) 2019-05-15
LT3416631T (lt) 2019-08-26
KR20250042197A (ko) 2025-03-26
RU2019106506A (ru) 2020-09-17
CN116459244A (zh) 2023-07-21
AU2023202121B2 (en) 2025-01-23
PT3416631T (pt) 2019-07-11
KR102785448B1 (ko) 2025-03-21
ME03454B (me) 2020-01-20
RU2021128045A (ru) 2021-11-16
MA43828A (fr) 2018-12-26
US20200179320A1 (en) 2020-06-11
CN109789114A (zh) 2019-05-21
MD3416631T2 (ro) 2019-09-30
SI3416631T1 (sl) 2019-09-30
SG11201901063SA (en) 2019-03-28
EP4467195A2 (en) 2024-11-27
IL264641B2 (en) 2024-07-01
US12144792B2 (en) 2024-11-19
EP3416631A1 (en) 2018-12-26
DK3416631T3 (da) 2019-07-15
KR20240068761A (ko) 2024-05-17
MA47521A (fr) 2021-04-21
JP2023175762A (ja) 2023-12-12
JP6957602B2 (ja) 2021-11-02
RU2019106506A3 (enExample) 2020-10-29
MA43828B1 (fr) 2019-09-30
KR102413756B1 (ko) 2022-06-27
AU2023202121A1 (en) 2023-05-04
WO2018029658A1 (en) 2018-02-15
AU2025202077A1 (en) 2025-04-10
CY1121930T1 (el) 2020-10-14
MX2021006901A (es) 2021-07-07
CN121081445A (zh) 2025-12-09
MX2024004439A (es) 2025-11-03
RU2756519C2 (ru) 2021-10-01
CA3033564A1 (en) 2018-02-15
TN2019000033A1 (fr) 2020-07-15
IL264641A (en) 2019-04-30
EP4467195A3 (en) 2025-03-19
CN116492328A (zh) 2023-07-28
MX2019001575A (es) 2019-08-01
KR20220093385A (ko) 2022-07-05
HRP20191055T1 (hr) 2019-09-06
PL3416631T3 (pl) 2019-11-29
JP2022003085A (ja) 2022-01-11
EP3583940A1 (en) 2019-12-25
US20240189267A1 (en) 2024-06-13
US20230210799A1 (en) 2023-07-06
HUE045043T2 (hu) 2019-12-30
MX383499B (es) 2025-03-14
JP2019524822A (ja) 2019-09-05
AU2017308865A1 (en) 2019-02-21
AU2017308865B2 (en) 2023-04-13
BR112019002730A2 (pt) 2019-05-14
IL310799A (en) 2024-04-01
ES2733677T3 (es) 2019-12-02

Similar Documents

Publication Publication Date Title
AU2023202121B2 (en) Therapeutic agents for neurodegenerative diseases
AU2018351709B2 (en) Therapeutic agents for neurodegenerative diseases
RU2849887C2 (ru) Терапевтические средства против нейродегенеративных заболеваний
HK40112206A (en) Therapeutic agents for neurodegenerative diseases
HK40018125A (en) Therapeutic agents for neurodegenerative diseases
HK40111843A (en) Therapeutic agents for neurodegenerative diseases
HK1259779B (en) Therapeutic agents for neurodegenerative diseases
HK1259779A1 (en) Therapeutic agents for neurodegenerative diseases
NZ790893A (en) Therapeutic Agents for Neurodegenerative Diseases
BR112020007657B1 (pt) Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls)